ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Egan, J.
Right arrow Articles by Woodcock, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Egan, J.
Right arrow Articles by Woodcock, A.
Eur Respir J 1999; 13: 1267-1275
Copyright © ERS Journals Ltd 1999

Clinical Trial

A randomized, double-blind study comparing the effects of beclomethasone and fluticasone on bone density over two years

JJ Egan, C Maden, S Kalra, JE Adams, R Eastell, and AA Woodcock

Cross-sectional studies have suggested that asthmatic patients receiving high dose inhaled corticosteroids and intermittent courses of oral corticosteroids have reduced bone mass. This prospective 2-yr study was undertaken to evaluate changes in bone density of patients receiving high doses of inhaled corticosteroids. Patients (n = 33) (males aged 18-50 yrs, females aged 18-40 yrs) on inhaled corticosteroids 1,000-2,000 microg x day(-1), were randomized in a double-blind fashion to either fluticasone propionate (FP) 1,000 microg x day(-1) or beclomethasone dipropionate (BDP) 2,000 microg x day(-1). In parallel, three open control groups of the same age range were studied: asthmatics (n = 8) receiving low dose inhaled corticosteroids (< or =400 microg x day(-1)) (group A); chronic, severe asthmatics (n = 8) receiving oral corticosteroids (> or =10 mg x day(-1) (group B); and healthy untreated volunteers (n = 7) (group C). Bone densitometry scans (quantitative computed tomography (QCT) of spine; dual X-ray absorptiometry of spine, femoral neck, and single photon absorptiometry of forearm) were performed at baseline and after 6, 12 and 24 months of treatment. Biochemical bone marker measurements (serum osteocalcin, bone alkaline phosphatase, pro-collagen type 1 carboxy terminal propeptide, deoxypyridinoline and C-telopeptide of type 1 collagen) were collected every 3 months. Fifteen FP (mean age 36 yrs, six male) and 9 BDP patients (mean age 33 yrs, five male); completed the study. At 0 months, mean bone mineral density (BMD) was lower in patients receiving inhaled corticosteroids (both low dose and high dose) than in normal volunteers. In the FP-treated group, mean vertebral trabecular BMD quantitative computed tomography remained stable with no evidence of decline, whereas there was some decline in the BDP-treated group. The treatment difference between FP and BDP was statistically significant in favour of FP for quantitative computed tomography measurements after 12 months (p = 0.006) and 24 months (p = 0.004). This study suggests that over 24 months, changes in bone density are minimal in patients on high-dose inhaled corticosteroids.


This article has been cited by other articles:


Home page
 ThoraxHome page
I A Campbell, J G Douglas, R M Francis, R J Prescott, and D M Reid
Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids
Thorax, September 1, 2004; 59(9): 761 - 768.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
J. P. Kemp, S. Osur, S. B. Shrewsbury, N. E. Herje, S. P. Duke, S. M. Harding, K. Faulkner, and C. C. Crim
Potential Effects of Fluticasone Propionate on Bone Mineral Density in Patients With Asthma: A 2-Year Randomized, Double-Blind, Placebo-Controlled Trial
Mayo Clin. Proc., April 1, 2004; 79(4): 458 - 466.
[Abstract] [PDF]

Home page
 CMAJHome page
E. Weir
COPD death rates: projecting a female trajectory
Can. Med. Assoc. J., February 3, 2004; 170(3): 334 - 334.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
A.A. Ionescu and E. Schoon
Osteoporosis in chronic obstructive pulmonary disease
Eur. Respir. J., November 2, 2003; 22(46_suppl): 64s - 75s.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
O. Johnell, R. Pauwels, C-G. Lofdahl, L.A. Laitinen, D.S. Postma, N.B. Pride, and S.V. Ohlsson
Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler(R)
Eur. Respir. J., June 1, 2002; 19(6): 1058 - 1063.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. M. Biskobing
COPD and Osteoporosis
Chest, February 1, 2002; 121(2): 609 - 620.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E. Israel, T. R. Banerjee, G. M. Fitzmaurice, T. V. Kotlov, K. LaHive, and M. S. LeBoff
Effects of Inhaled Glucocorticoids on Bone Density in Premenopausal Women
N. Engl. J. Med., September 27, 2001; 345(13): 941 - 947.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
A E Tattersfield, G I Town, O Johnell, C Picado, M Aubier, P Braillon, and R Karlström
Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years
Thorax, April 1, 2001; 56(4): 272 - 278.
[Abstract] [Full Text]

Home page
 DTBHome page
The use of inhaled corticosteroids in adults with asthma
DTB, January 1, 2000; 38(1): 5 - 8.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the European Respiratory Society.